New combo therapy aims to calm immune attack on kidneys

NCT ID NCT00977977

Recruiting now Disease control Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Source: ClinicalTrials.gov ↗

First seen Jan 03, 2026 · Last updated May 20, 2026 · Updated 21 times

Summary

This study tests whether combining two immune-suppressing drugs, rituximab and cyclosporine, can safely reduce protein leakage in the urine of people with membranous nephropathy, a kidney disease where the immune system damages kidney filters. About 30 adults with persistent protein in their urine will receive the drugs over 6 months and be followed for up to 24 months. The goal is to see if the combination leads to remission of protein loss and is safe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States
National Naval Medical Center
RECRUITING

Bethesda, Maryland, 20889, United States

Conditions

Explore the condition pages connected to this study.

AUTOIMMUNE DISEASE GLOMERULAR DISEASE MEMBRANOUS GLOMERULONEPHRITIS NEPHROTIC SYNDROME PROTEINURIA